Show simple item record

dc.contributor.authorMoorlag, SJCFM
dc.contributor.authorvan Deuren, RC
dc.contributor.authorvan Werkhoven, CH
dc.contributor.authorJaeger, M
dc.contributor.authorDebisarun, P
dc.contributor.authorTaks, E
dc.contributor.authorMourits, VP
dc.contributor.authorKoeken, VACM
dc.contributor.authorde Bree, LCJ
dc.contributor.authorten Doesschate, T
dc.contributor.authorCleophas, MC
dc.contributor.authorSmeekens, S
dc.contributor.authorOosting, M
dc.contributor.authorvan de Veerdonk, FL
dc.contributor.authorJoosten, LAB
dc.contributor.authorten Oever, J
dc.contributor.authorvan der Meer, JWM
dc.contributor.authorCurtis, N
dc.contributor.authorAaby, P
dc.contributor.authorStabell-Benn, C
dc.contributor.authorGiamarellos-Bourboulis, EJ
dc.contributor.authorBonten, M
dc.contributor.authorvan Crevel, R
dc.contributor.authorNetea, MG
dc.date.accessioned2020-12-09T22:16:11Z
dc.date.available2020-12-09T22:16:11Z
dc.date.issued2020-08-25
dc.identifierpii: 100073
dc.identifier.citationMoorlag, S. J. C. F. M., van Deuren, R. C., van Werkhoven, C. H., Jaeger, M., Debisarun, P., Taks, E., Mourits, V. P., Koeken, V. A. C. M., de Bree, L. C. J., ten Doesschate, T., Cleophas, M. C., Smeekens, S., Oosting, M., van de Veerdonk, F. L., Joosten, L. A. B., ten Oever, J., van der Meer, J. W. M., Curtis, N., Aaby, P. ,... Netea, M. G. (2020). Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. CELL REPORTS MEDICINE, 1 (5), https://doi.org/10.1016/j.xcrm.2020.100073.
dc.identifier.issn2666-3791
dc.identifier.urihttp://hdl.handle.net/11343/252907
dc.description.abstractBacille Calmette-Guérin (BCG) induces long-term boosting of innate immunity, termed trained immunity, and decreases susceptibility to respiratory tract infections. BCG vaccination trials for reducing SARS-CoV-2 infection are underway, but concerns have been raised regarding the potential harm of strong innate immune responses. To investigate the safety of BCG vaccination, we retrospectively assessed coronavirus disease 2019 (COVID-19) and related symptoms in three cohorts of healthy volunteers who either received BCG in the last 5 years or did not. BCG vaccination is not associated with increased incidence of symptoms during the COVID-19 outbreak in the Netherlands. Our data suggest that BCG vaccination might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic (adjusted odds ratio [AOR] 0.58, p < 0.05), and lower incidence of extreme fatigue. In conclusion, recent BCG vaccination is safe, and large randomized trials are needed to reveal if BCG reduces the incidence and/or severity of SARS-CoV-2 infection.
dc.languageEnglish
dc.publisherELSEVIER
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleSafety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study
dc.typeJournal Article
dc.identifier.doi10.1016/j.xcrm.2020.100073
melbourne.affiliation.departmentPaediatrics (RCH)
melbourne.source.titleCELL REPORTS MEDICINE
melbourne.source.volume1
melbourne.source.issue5
melbourne.source.pages100073-
dc.rights.licenseCC BY
melbourne.elementsid1463087
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405881
melbourne.contributor.authorCurtis, Richard
dc.identifier.eissn2666-3791
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record